Effect of Cognitive Therapy With Antidepressant Medications vs Antidepressants Alone on the Rate of Recovery in Major Depressive Disorder: A Randomized Clinical Trial | Depressive Disorders | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Keller  MB.  Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond.  JAMA. 2003;289(23):3152-3160.PubMedGoogle ScholarCrossref
Rush  AJ, Kraemer  HC, Sackeim  HA,  et al; ACNP Task Force.  Report by the ACNP Task Force on response and remission in major depressive disorder.  Neuropsychopharmacology. 2006;31(9):1841-1853.PubMedGoogle ScholarCrossref
Marcus  SC, Olfson  M.  National trends in the treatment for depression from 1998 to 2007.  Arch Gen Psychiatry. 2010;67(12):1265-1273.PubMedGoogle ScholarCrossref
Psychiatry Online. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with major depressive disorder: 3rd rev. Washington, DC: American Psychiatric Association; 2010. www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx. Accessed October 9, 2012.
Rush  AJ, Trivedi  MH, Wisniewski  SR,  et al.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.  Am J Psychiatry. 2006;163(11):1905-1917.PubMedGoogle ScholarCrossref
Hollon  SD, Jarrett  RB, Nierenberg  AA, Thase  ME, Trivedi  M, Rush  AJ.  Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment?  J Clin Psychiatry. 2005;66(4):455-468.PubMedGoogle ScholarCrossref
Blackburn  IM, Bishop  S, Glen  AI, Whalley  LJ, Christie  JE.  The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination.  Br J Psychiatry. 1981;139:181-189.PubMedGoogle ScholarCrossref
Hollon  SD, DeRubeis  RJ, Evans  MD,  et al.  Cognitive therapy and pharmacotherapy for depression: singly and in combination.  Arch Gen Psychiatry. 1992;49(10):774-781.PubMedGoogle ScholarCrossref
Murphy  GE, Simons  AD, Wetzel  RD, Lustman  PJ.  Cognitive therapy and pharmacotherapy: singly and together in the treatment of depression.  Arch Gen Psychiatry. 1984;41(1):33-41.PubMedGoogle ScholarCrossref
Keller  MB, McCullough  JP, Klein  DN,  et al.  A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.  N Engl J Med. 2000;342(20):1462-1470.PubMedGoogle ScholarCrossref
Kocsis  JH, Gelenberg  AJ, Rothbaum  BO,  et al; REVAMP Investigators.  Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial.  Arch Gen Psychiatry. 2009;66(11):1178-1188.PubMedGoogle ScholarCrossref
Rush  AJ.  STAR*D: what have we learned?  Am J Psychiatry. 2007;164(2):201-204.PubMedGoogle ScholarCrossref
Fournier  JC, DeRubeis  RJ, Shelton  RC, Gallop  R, Amsterdam  JD, Hollon  SD.  Antidepressant medications versus cognitive therapy in people with depression with or without personality disorder.  Br J Psychiatry. 2008;192(2):124-129.PubMedGoogle ScholarCrossref
Westen  D, Novotny  CM, Thompson-Brenner  H.  The empirical status of empirically supported psychotherapies: assumptions, findings, and reporting in controlled clinical trials.  Psychol Bull. 2004;130(4):631-663.PubMedGoogle ScholarCrossref
First  MB, Spitzer  RL, Gibbon  M, Williams  JBW.  Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/ PSY SCREEN). New York: Biometrics Research, New York State Psychiatric Institute; 2001.
Spitzer  RL, Williams  JBW, Gibbon  M, First  MB.  Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II, Version 1.0). Washington, DC: American Psychiatric Press; 1990.
American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders.ed 4. Washington, DC: American Psychiatric Association; 1994.
Hollon  SD, DeRubeis  RJ, Shelton  RC,  et al.  Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.  Arch Gen Psychiatry. 2005;62(4):417-422.PubMedGoogle ScholarCrossref
Hamilton  M.  A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;23(2):56-62.PubMedGoogle ScholarCrossref
Reimherr  FW, Amsterdam  JD, Quitkin  FM,  et al.  Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.  Am J Psychiatry. 1998;155(9):1247-1253.PubMedGoogle ScholarCrossref
Keller  MB, Lavori  PW, Friedman  B,  et al.  The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies.  Arch Gen Psychiatry. 1987;44(6):540-548.PubMedGoogle ScholarCrossref
Fleiss  JL, Cohen  J.  Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons; 1973.
Fawcett  J, Epstein  P, Fiester  SJ, Elkin  I, Autry  JH; NIMH Treatment of Depression Collaborative Research Program.  Clinical management—imipramine/placebo administration manual.  Psychopharmacol Bull. 1987;23(2):309-324.PubMedGoogle Scholar
Beck  AT, Rush  AJ, Shaw  BF, Emery  G.  Cognitive Therapy of Depression. New York, NY: Guilford Press; 1979.
Beck  AT, Freeman  A, Davis  DD.  Cognitive Therapy of Personality Disorders. 2nd ed. New York, NY: Guilford Press; 2003.
Greenhouse  JB, Stangl  D, Bromberg  J.  An introduction to survival analysis: statistical methods for analysis of clinical trial data.  J Consult Clin Psychol. 1989;57(4):536-544.PubMedGoogle ScholarCrossref
Szychowski  JM, Roth  DL, Clay  OJ, Mittelman  MS.  Patient death as a censoring event or competing risk event in models of nursing home placement.  Stat Med. 2010;29(3):371-381.PubMedGoogle Scholar
Fine  JP, Gray  RJ.  A proportional hazards model for the subdistribution of a competing risk.  J Am Stat Assoc. 1999;94(446):496-509.Google ScholarCrossref
Zhang  X, Zhang  MJ.  SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models.  Comput Methods Programs Biomed. 2011;101(1):87-93.PubMedGoogle ScholarCrossref
Kraemer  HC, Kupfer  DJ.  Size of treatment effects and their importance to clinical research and practice.  Biol Psychiatry. 2006;59(11):990-996.PubMedGoogle ScholarCrossref
Kazdin  AE, Bass  D.  Power to detect differences between alternative treatments in comparative psychotherapy outcome research.  J Consult Clin Psychol. 1989;57(1):138-147.PubMedGoogle ScholarCrossref
Thase  ME, Greenhouse  JB, Frank  E,  et al.  Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations.  Arch Gen Psychiatry. 1997;54(11):1009-1015.PubMedGoogle ScholarCrossref
DeRubeis  RJ, Cohen  ZD, Forand  NR, Fournier  JC, Gelfand  LA, Lorenzo-Luaces  L.  The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration.  PLoS One. 2014;9(1):e83875. doi:10.1371/journal.pone.0083875.PubMedGoogle ScholarCrossref
Kazdin  AE.  Mediators and mechanisms of change in psychotherapy research.  Annu Rev Clin Psychol. 2007;3:1-27.PubMedGoogle ScholarCrossref
Cuijpers  P, Hollon  SD, van Straten  A, Bockting  C, Berking  M, Andersson  G.  Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? a meta-analysis.  BMJ Open. 2013;3(4):e002542. doi:10.1136/bmjopen-2012-002542.PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Cruciality of Blinding with Subjective Endpoints
    Douglas M. Berger, M.D., Ph.D. | Meguro Counseling Center, Tokyo, Japan

    This study by Hollon et al., was not double blind, i.e., neither the subjects nor treaters were blind to the treatment(s) given. Unfortunately, no psychotherapy study, and in particular no CBT study where treaters and patients have to undergo cognitive and behavioral exercises, can be double-, or single-, blinded. Raters were “masked”, but this does not make the study single blind because single blind is defined as when the subjects are blind (1). Masked raters only record the report that comes out of the subject-treater system, biased or not. Calling raters “blind” instead of “masked” could be true, however, this nomenclature still does not make the study single-blinded, misleading readers into thinking the study was blinded and/or well-controlled.

    Blinding is a crucial point in understanding the design of a trial of depression with subjective endpoints. Full allocation blinding of a treatment in a clinical trial is critical for a study of Major Depression where endpoints are subjective (2). The elements of expectation and hope in an unblinded study with subjective endpoints can easily bias subjects’ statements of depressive symptom changes to the raters, and a large N as in this study can easily validate a biased outcome to “statistical significance.” Some researchers may voice the objection that medications may also be unmasked because of certain side-effects noticed by the subjects. This can be true with some medications, but not every trial would be unmasked to subjects as is necessarily the case for CBT, and trials showing significant unmasking should be invalidated whether drug or psychotherapy.

    Blinding may not be required when studying certain conditions that have strongly objective endpoints, i.e., stroke incidence, bone fracture incidence, death rate, etc. where the intervention’s efficacy would be great compared with random error and bias (3); unfortunately random error and bias is very large in the subjective endpoints studied in depression. 

    The results obtained by Hollon et al. could also be interpreted as that subjects with milder depression included more patients who did not have a medically-responsive depression (4), while for those with greater severity, there was both drug efficacy as well as hope and expectation in the cognitive therapy group biasing the results to the combination therapy. This interpretation is just as plausible as the conclusion that combination therapy is more effective for severe depression. The study design of this clinical trial without double blinding in subjective endpoints is too limited to make any conclusions of superior efficacy for combination therapy. 

    As a final note, it is not a valid study design to mix and compare study arms that have different levels of bias control (i.e., double-blinded drug therapy with unblinded psychotherapy) without being clear this is a severe limitation. This type of research could be called “observation of community treatment”, but it should not be termed a “clinical trial” because that would put unblinded studies with subjective endpoints at the same level of validity as clinical trials with strong double-blinding (5). 

    (1) Friedman LM, Furgerg CD, DeMets DL. Fundamentals of Clinical Trials, Third Edition. Springer; 1998 (or internet search for:“definition of single-blind”). 

    (2) Schulz, KF, Grimes DA, Blinding in Randomised Trials: hiding who got what. The Lancet, 2002:359; 696-700. Feburary 23, 2002. 

    (3) Piantadosi S. Clinical Trials: A Methodologic Perspective, 2nd ed. New York: Wiley-Interscience; 2005. 

    (4) Khan A, Leventhal R, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22:40-45

    (5) Hanrahan C, New JP. Antidepressant Medications: The FDA-Approval Process and the Need for Updates. Ment Health Clin. 2014;4(1):45. Available at: http://mhc.cpnp.org/doi/full/10.9740/mhc.n186950 (accessed April 8th 2015)

    Original Investigation
    October 2014

    Effect of Cognitive Therapy With Antidepressant Medications vs Antidepressants Alone on the Rate of Recovery in Major Depressive Disorder: A Randomized Clinical Trial

    Author Affiliations
    • 1Department of Psychology, Vanderbilt University, Nashville, Tennessee
    • 2Department of Psychology, University of Pennsylvania, Philadelphia
    • 3Department of Psychiatry, University of New Mexico, Albuquerque
    • 4Department of Psychiatry, University of Pennsylvania, Philadelphia
    • 5Department of Psychiatry, Vanderbilt University, Nashville, Tennessee
    • 6currently at the Department of Psychiatry, University of Alabama, Birmingham
    • 7Department of Psychiatry, Rush University, Chicago, Illinois
    • 8Department of Mathematics and Applied Statistics, West Chester University, West Chester, Pennsylvania
    JAMA Psychiatry. 2014;71(10):1157-1164. doi:10.1001/jamapsychiatry.2014.1054

    Importance  Antidepressant medication (ADM) is efficacious in the treatment of depression, but not all patients achieve remission and fewer still achieve recovery with ADM alone.

    Objective  To determine the effects of combining cognitive therapy (CT) with ADM vs ADM alone on remission and recovery in major depressive disorder (MDD).

    Design, Setting, and Participants  A total of 452 adult outpatients with chronic or recurrent MDD participated in a trial conducted in research clinics at 3 university medical centers in the United States. The patients were randomly assigned to ADM treatment alone or CT combined with ADM treatment. Treatment was continued for up to 42 months until recovery was achieved. Survival analyses based on subdistribution hazard models were used to model treatment outcomes.

    Interventions  Antidepressant medication with or without CT.

    Main Outcomes and Measures  Blind evaluations of recovery with a modified version of the 17-item Hamilton Rating Scale for Depression and the Longitudinal Interval Follow-up Evaluation.

    Results  Of the 452 participants, 227 were randomized to the CT combined with ADM treatment group, and 225 to the ADM treatment alone group. Combined treatment enhanced the rate of recovery vs treatment with ADM alone (75.2% vs 65.6%; t451 = 2.44; P = .02; hazard ratio [HR], 1.32; 95% CI, 1.06-1.65; number needed to treat [NNT], 11; 95% CI, 6-91). This effect was conditioned on a statistically nonsignificant interaction with severity (t451 = 1.67; P = .09; NNT, 6) and a significant interaction with chronicity (χ2 = 7.66; P = .02; NNT, 6) such that the advantage for combined treatment was limited to patients with severe, nonchronic MDD (84.7% vs 57.7%; n = 147; t146 = 3.88; P = .001; HR, 2.21; 95% CI, 1.48-3.31; NNT, 4; 95% CI, 2-8). There was no difference in the number of patients who dropped out of combined treatment vs ADM treatment alone (18.1% vs 24.8%; t451 = −1.77; P = .08; HR, 0.70; 95% CI, 0.47-1.04). Remission rates did not differ significantly either as a main effect of treatment or as an interaction with severity or chronicity. Patients with comorbid Axis II disorders took longer to recover than did patients without comorbid Axis II disorders regardless of the condition (P = .001). There were no statistically significant differences in the numbers of serious adverse events in the 2 groups (41 in the ADM plus CT group vs 52 in the ADM-alone group; χ1 = 1.76; P = .18).

    Conclusions and Relevance  Cognitive therapy combined with ADM treatment enhances the rates of recovery from MDD relative to ADMs alone, with the effect limited to patients with severe, nonchronic depression.

    Trial Registration  clinicaltrials.gov Identifier: NCT00057577